Vivacta Bio
In vivo CAR-T therapies for cancer
About
Vivacta Bio, founded around 2020, is a Shanghai-based biotech company specializing in in vivo CAR-T therapies, primarily developing GT801. The company is advancing GT801 through clinical trials and regulatory approvals, leveraging significant Series A and A+ funding to expand its research team and global footprint. Vivacta’s platform enables direct in vivo CAR-T cell modification, aiming to simplify CAR-T treatments and improve accessibility and efficacy for cancer patients worldwide, monetizing through biopharmaceutical development and partnerships.
Products
- GT801
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Vivacta Bio — available to members.
